OncoMatch/Clinical Trials/NCT04655092
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Is NCT04655092 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies P1101 (Ropeginterferon alfa-2b) for polycythemia vera (pv).
Treatment: P1101 (Ropeginterferon alfa-2b) — This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myeloproliferative Neoplasm
Demographics
Prior therapy
Must have received:
Patients who have completed the 52-week treatment duration in Study A19-201
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04655092 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received .
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages